Viral Load Drives Disease in Humans Experimentally Infected with Respiratory Syncytial Virus

2010333 citationsJournal Articlegreen Open Access

Authors

John P. DeVincenzo · Children's Medical Center

Tom Wilkinson · City College Southampton

Akshay Vaishnaw · Alnylam Pharmaceuticals (United States)

Jeff Cehelsky · Alnylam Pharmaceuticals (United States)

Rachel Meyers · Alnylam Pharmaceuticals (United States)

Saraswathy V. Nochur · Alnylam Pharmaceuticals (United States)

Lisa M. Harrison

Abstract

Viral load appears to drive disease manifestations in humans with RSV infection. The observed parallel viral and disease kinetics support a potential clinical benefit of RSV antivirals. This reproducible model facilitates the development of future RSV therapeutics.

Topics & Keywords

Respiratory viral infections research Parvovirus B19 Infection Studies Neonatal Respiratory Health Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: American Journal of Respiratory and Critical Care Medicine

Volume 182, Issue 10, pp. 1305-1314

DOI: 10.1164/rccm.201002-0221oc

Field-Weighted Citation Impact: 9.30